JP2021530454A - カッコウアザミ属(Ageratum spp.)からの抽出物を使用して良性前立腺肥大症(BPH)及び関連する加齢症状を改善及び管理するための薬用植物抽出組成物及び方法 - Google Patents
カッコウアザミ属(Ageratum spp.)からの抽出物を使用して良性前立腺肥大症(BPH)及び関連する加齢症状を改善及び管理するための薬用植物抽出組成物及び方法 Download PDFInfo
- Publication number
- JP2021530454A JP2021530454A JP2020572400A JP2020572400A JP2021530454A JP 2021530454 A JP2021530454 A JP 2021530454A JP 2020572400 A JP2020572400 A JP 2020572400A JP 2020572400 A JP2020572400 A JP 2020572400A JP 2021530454 A JP2021530454 A JP 2021530454A
- Authority
- JP
- Japan
- Prior art keywords
- ageratum
- conyzoides
- spp
- bph
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000544602 Ageratum Species 0.000 title claims abstract description 60
- 208000024891 symptom Diseases 0.000 title claims abstract description 38
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 title claims description 63
- 208000004403 Prostatic Hyperplasia Diseases 0.000 title claims description 63
- 238000000034 method Methods 0.000 title claims description 44
- 239000000203 mixture Substances 0.000 title claims description 19
- 239000000419 plant extract Substances 0.000 title abstract description 25
- 239000000284 extract Substances 0.000 title description 27
- 230000032683 aging Effects 0.000 title description 6
- 244000296912 Ageratum conyzoides Species 0.000 claims description 52
- 235000004405 Ageratum conyzoides Nutrition 0.000 claims description 32
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 claims description 26
- 230000000694 effects Effects 0.000 claims description 18
- 206010036018 Pollakiuria Diseases 0.000 claims description 12
- 230000002485 urinary effect Effects 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- 230000027939 micturition Effects 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 208000022934 urinary frequency Diseases 0.000 claims description 3
- 208000019206 urinary tract infection Diseases 0.000 claims description 3
- 201000002327 urinary tract obstruction Diseases 0.000 claims description 3
- 230000036318 urination frequency Effects 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 56
- 150000001875 compounds Chemical class 0.000 abstract description 27
- 239000002904 solvent Substances 0.000 abstract description 26
- 241000196324 Embryophyta Species 0.000 abstract description 21
- 238000000605 extraction Methods 0.000 abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 19
- 239000008223 sterile water Substances 0.000 abstract description 15
- -1 7-methoxy-2,2-dimethyl-2H-chromen-6-yl Chemical group 0.000 abstract description 12
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 abstract description 10
- 230000036541 health Effects 0.000 abstract description 10
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 abstract description 10
- VMUXSMXIQBNMGZ-UHFFFAOYSA-N 3,4-dihydrocoumarin Chemical compound C1=CC=C2OC(=O)CCC2=C1 VMUXSMXIQBNMGZ-UHFFFAOYSA-N 0.000 abstract description 9
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 abstract description 9
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 abstract description 8
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 abstract description 8
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 abstract description 7
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 abstract description 7
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 6
- 239000001707 (E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-ol Substances 0.000 abstract description 5
- 235000021314 Palmitic acid Nutrition 0.000 abstract description 5
- BLUHKGOSFDHHGX-UHFFFAOYSA-N Phytol Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)C=CO BLUHKGOSFDHHGX-UHFFFAOYSA-N 0.000 abstract description 5
- HNZBNQYXWOLKBA-UHFFFAOYSA-N Tetrahydrofarnesol Natural products CC(C)CCCC(C)CCCC(C)=CCO HNZBNQYXWOLKBA-UHFFFAOYSA-N 0.000 abstract description 5
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 abstract description 5
- BOTWFXYSPFMFNR-OALUTQOASA-N all-rac-phytol Natural products CC(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)=CCO BOTWFXYSPFMFNR-OALUTQOASA-N 0.000 abstract description 5
- 235000020661 alpha-linolenic acid Nutrition 0.000 abstract description 5
- 238000013459 approach Methods 0.000 abstract description 5
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 abstract description 5
- 229960004488 linolenic acid Drugs 0.000 abstract description 5
- BOTWFXYSPFMFNR-PYDDKJGSSA-N phytol Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CO BOTWFXYSPFMFNR-PYDDKJGSSA-N 0.000 abstract description 5
- 229940031439 squalene Drugs 0.000 abstract description 5
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 abstract description 5
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 abstract description 4
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 abstract description 4
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 abstract description 4
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 abstract description 4
- 229940032091 stigmasterol Drugs 0.000 abstract description 4
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 abstract description 4
- 235000016831 stigmasterol Nutrition 0.000 abstract description 4
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 abstract description 3
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 abstract description 3
- 230000010485 coping Effects 0.000 abstract description 3
- 229930182478 glucoside Natural products 0.000 abstract description 3
- 150000008131 glucosides Chemical class 0.000 abstract description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 abstract description 3
- 235000020778 linoleic acid Nutrition 0.000 abstract description 3
- 229960001285 quercetin Drugs 0.000 abstract description 3
- 235000005875 quercetin Nutrition 0.000 abstract description 3
- 238000010586 diagram Methods 0.000 abstract 1
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 38
- 239000000902 placebo Substances 0.000 description 25
- 229940068196 placebo Drugs 0.000 description 25
- 230000014509 gene expression Effects 0.000 description 23
- 229960003604 testosterone Drugs 0.000 description 19
- 235000019441 ethanol Nutrition 0.000 description 18
- 238000012360 testing method Methods 0.000 description 14
- 210000002307 prostate Anatomy 0.000 description 13
- 240000006661 Serenoa repens Species 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 210000005267 prostate cell Anatomy 0.000 description 11
- 235000005318 Serenoa repens Nutrition 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 239000010018 saw palmetto extract Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 9
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 238000000638 solvent extraction Methods 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 239000003098 androgen Substances 0.000 description 6
- 229960003473 androstanolone Drugs 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 6
- KUPLEGDPSCCPJI-UHFFFAOYSA-N tetracontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC KUPLEGDPSCCPJI-UHFFFAOYSA-N 0.000 description 6
- 239000002028 Biomass Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- JSNRRGGBADWTMC-UHFFFAOYSA-N (6E)-7,11-dimethyl-3-methylene-1,6,10-dodecatriene Chemical compound CC(C)=CCCC(C)=CCCC(=C)C=C JSNRRGGBADWTMC-UHFFFAOYSA-N 0.000 description 4
- 239000001149 (9Z,12Z)-octadeca-9,12-dienoate Substances 0.000 description 4
- WTTJVINHCBCLGX-UHFFFAOYSA-N (9trans,12cis)-methyl linoleate Natural products CCCCCC=CCC=CCCCCCCCC(=O)OC WTTJVINHCBCLGX-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- JNHLHPMTMTYLCP-UHFFFAOYSA-N 1-(4-tert-butyl-2,6-dimethylphenyl)ethanone Chemical compound CC(=O)C1=C(C)C=C(C(C)(C)C)C=C1C JNHLHPMTMTYLCP-UHFFFAOYSA-N 0.000 description 4
- BZUNJUAMQZRJIP-UHFFFAOYSA-N 15-hydroxypentadecanoic acid Chemical compound OCCCCCCCCCCCCCCC(O)=O BZUNJUAMQZRJIP-UHFFFAOYSA-N 0.000 description 4
- CMRBCUQYNLDSKE-UHFFFAOYSA-N 3,5,7-trimethoxy-2-(3,4,5-trimethoxyphenyl)chromen-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(C=2OC)=O)C=1OC=2C1=CC(OC)=C(OC)C(OC)=C1 CMRBCUQYNLDSKE-UHFFFAOYSA-N 0.000 description 4
- NCTSLPBQVXUAHR-UHFFFAOYSA-N 3,5-ditert-butylbenzoic acid Chemical compound CC(C)(C)C1=CC(C(O)=O)=CC(C(C)(C)C)=C1 NCTSLPBQVXUAHR-UHFFFAOYSA-N 0.000 description 4
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 4
- LNJCGNRKWOHFFV-UHFFFAOYSA-N 3-(2-hydroxyethylsulfanyl)propanenitrile Chemical compound OCCSCCC#N LNJCGNRKWOHFFV-UHFFFAOYSA-N 0.000 description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 4
- RRUFTPKJXNXMAE-UHFFFAOYSA-N 6-ethenyl-7-methoxy-2,2-dimethylchromene Chemical compound O1C(C)(C)C=CC2=C1C=C(OC)C(C=C)=C2 RRUFTPKJXNXMAE-UHFFFAOYSA-N 0.000 description 4
- PKIXXJPMNDDDOS-UHFFFAOYSA-N Methyl linoleate Natural products CCCCC=CCCC=CCCCCCCCC(=O)OC PKIXXJPMNDDDOS-UHFFFAOYSA-N 0.000 description 4
- FLIACVVOZYBSBS-UHFFFAOYSA-N Methyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC FLIACVVOZYBSBS-UHFFFAOYSA-N 0.000 description 4
- NIDGCIPAMWNKOA-WOJBJXKFSA-N Neophytadiene Natural products [C@H](CCC[C@@H](CCCC(C)C)C)(CCCC(C=C)=C)C NIDGCIPAMWNKOA-WOJBJXKFSA-N 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- NIDGCIPAMWNKOA-UHFFFAOYSA-N neophytadiene Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(=C)C=C NIDGCIPAMWNKOA-UHFFFAOYSA-N 0.000 description 4
- MRIAQLRQZPPODS-UHFFFAOYSA-N nobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 MRIAQLRQZPPODS-UHFFFAOYSA-N 0.000 description 4
- 230000000422 nocturnal effect Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 240000001980 Cucurbita pepo Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229940030486 androgens Drugs 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229960000890 hydrocortisone Drugs 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 230000036299 sexual function Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 210000003708 urethra Anatomy 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- FUCYIEXQVQJBKY-ZFWWWQNUSA-N (+)-δ-Cadinene Chemical compound C1CC(C)=C[C@H]2[C@H](C(C)C)CCC(C)=C21 FUCYIEXQVQJBKY-ZFWWWQNUSA-N 0.000 description 2
- SKCKOFZKJLZSFA-KVTDHHQDSA-N (2r,3r,4r,5r)-hexane-1,2,3,4,5-pentol Chemical compound C[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO SKCKOFZKJLZSFA-KVTDHHQDSA-N 0.000 description 2
- JSNRRGGBADWTMC-QINSGFPZSA-N (E)-beta-Farnesene Natural products CC(C)=CCC\C(C)=C/CCC(=C)C=C JSNRRGGBADWTMC-QINSGFPZSA-N 0.000 description 2
- CQAIPASUUZBIJF-UHFFFAOYSA-N 1-[butyl(hexoxy)phosphoryl]oxy-4-(2-phenylpropan-2-yl)benzene Chemical compound C1=CC(OP(=O)(CCCC)OCCCCCC)=CC=C1C(C)(C)C1=CC=CC=C1 CQAIPASUUZBIJF-UHFFFAOYSA-N 0.000 description 2
- 101150028074 2 gene Proteins 0.000 description 2
- PFEFOYRSMXVNEL-UHFFFAOYSA-N 2,4,6-tritert-butylphenol Chemical compound CC(C)(C)C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 PFEFOYRSMXVNEL-UHFFFAOYSA-N 0.000 description 2
- PRTCFQOQYWNVJL-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yl)-5-hydroxy-3,6,7,8-tetramethoxychromen-4-one Chemical compound C1=C2OCOC2=CC(C=2OC3=C(C(C=2OC)=O)C(O)=C(C(=C3OC)OC)OC)=C1 PRTCFQOQYWNVJL-UHFFFAOYSA-N 0.000 description 2
- RBJOTRVJJWIIER-UHFFFAOYSA-N 3-phenylisoquinoline Chemical compound C1=CC=CC=C1C1=CC2=CC=CC=C2C=N1 RBJOTRVJJWIIER-UHFFFAOYSA-N 0.000 description 2
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 2
- 235000003840 Amygdalus nana Nutrition 0.000 description 2
- 235000000832 Ayote Nutrition 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 235000009854 Cucurbita moschata Nutrition 0.000 description 2
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 101600111816 Homo sapiens Sex hormone-binding globulin (isoform 1) Proteins 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 235000011432 Prunus Nutrition 0.000 description 2
- 241000220299 Prunus Species 0.000 description 2
- 241000233910 Serenoa Species 0.000 description 2
- 102300044179 Sex hormone-binding globulin isoform 1 Human genes 0.000 description 2
- 240000003768 Solanum lycopersicum Species 0.000 description 2
- QMAYBMKBYCGXDH-UHFFFAOYSA-N alpha-amorphene Natural products C1CC(C)=CC2C(C(C)C)CC=C(C)C21 QMAYBMKBYCGXDH-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000002921 anti-spasmodic effect Effects 0.000 description 2
- YSNRTFFURISHOU-UHFFFAOYSA-N beta-farnesene Natural products C=CC(C)CCC=C(C)CCC=C(C)C YSNRTFFURISHOU-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960000956 coumarin Drugs 0.000 description 2
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 2
- YOCDGWMCBBMMGJ-UHFFFAOYSA-N delta-cadinene Natural products C1C=C(C)CC2C(C(C)C)CCC(=C)C21 YOCDGWMCBBMMGJ-UHFFFAOYSA-N 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
- 229960004039 finasteride Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- YDLYQMBWCWFRAI-UHFFFAOYSA-N hexatriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC YDLYQMBWCWFRAI-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- FYQGBXGJFWXIPP-UHFFFAOYSA-N hydroprene Chemical compound CCOC(=O)C=C(C)C=CCC(C)CCCC(C)C FYQGBXGJFWXIPP-UHFFFAOYSA-N 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- GARQDIVXKVBJFP-UHFFFAOYSA-N p-Octylacetophenone Chemical compound CCCCCCCCC1=CC=C(C(C)=O)C=C1 GARQDIVXKVBJFP-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000037209 prostate health Effects 0.000 description 2
- 208000026455 prostate symptom Diseases 0.000 description 2
- 235000014774 prunus Nutrition 0.000 description 2
- 235000015136 pumpkin Nutrition 0.000 description 2
- BNSCASRSSGJHQH-UHFFFAOYSA-N quercetinyl-3-O-alpha-galactosyl-7-O-alpha-glucoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(OC3C(C(O)C(O)C(CO)O3)O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BNSCASRSSGJHQH-UHFFFAOYSA-N 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- USDOQCCMRDNVAH-UHFFFAOYSA-N sigma-cadinene Natural products C1C=C(C)CC2C(C(C)C)CC=C(C)C21 USDOQCCMRDNVAH-UHFFFAOYSA-N 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- POOSGDOYLQNASK-UHFFFAOYSA-N tetracosane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC POOSGDOYLQNASK-UHFFFAOYSA-N 0.000 description 2
- GWVDBZWVFGFBCN-UHFFFAOYSA-N tetratriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC GWVDBZWVFGFBCN-UHFFFAOYSA-N 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- 108020005096 28S Ribosomal RNA Proteins 0.000 description 1
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000132536 Cirsium Species 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000544061 Cuculus canorus Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 235000005105 Pinus pinaster Nutrition 0.000 description 1
- 241001236212 Pinus pinaster Species 0.000 description 1
- 235000000719 Prunus africana Nutrition 0.000 description 1
- 241000200478 Prunus africana Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 235000002560 Solanum lycopersicum Nutrition 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 241000219422 Urtica Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 1
- 229960005471 androstenedione Drugs 0.000 description 1
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 229960002847 prasterone Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000000064 prostate epithelial cell Anatomy 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 239000013643 reference control Substances 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 210000004511 skin melanocyte Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000037359 steroid metabolism Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 206010046459 urethral obstruction Diseases 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
この試験では、ヒト前立腺上皮細胞におけるカッコウアザミ(Ageratum conyzoides)(カッコウアザミ(A.conyzoides))の48時間の処置後に、リアルタイムポリメラーゼ連鎖反応(qRT−PCR)によって5−アルファ−レダクターゼ遺伝子1型及び2型の発現を測定した。
Brisbane,Australiaにて、カッコウアザミ属(Ageratum spp.)の薬用植物抽出物を用いたヒト前立腺細胞に対する臨床試験を12週間の短期間で実施した。この試験では、カッコウアザミ属(Ageratum spp.)から作製した薬用植物抽出物の、中高年男性におけるBPHの症状、付随する加齢関連症状、並びにPSAレベル、性ホルモン、脂質及び血糖値の変化に対する有効性を評価した。カッコウアザミ属(Ageratum spp.)抽出物はBPH及び関連症状の処置に極めて良好であることが判明した。
ランダム化プラセボ対照臨床試験により、カッコウアザミ(A.conyzoides)抽出物は、他の点では健康である男性ヒト対象に12週間投与した場合、それら男性のBPHの症状の重症度を著しく低下させることが実証された。臨床的改善には、昼間及び夜間の排尿頻度の両方の著しい減少、並びに生活の質の全般的な向上が伴った。遺伝子発現試験により、カッコウアザミ(A.conyzoides)がヒト前立腺上皮細胞におけるDHTのmRNA発現を阻害し、BPHの症状の管理のための5−アルファ−レダクターゼ阻害薬と類似の作用機序を有し得ることが示された。
Claims (17)
- 男性ヒト対象における良性前立腺肥大症に伴う症状を処置するための方法において、そのような処置が必要な前記対象にカッコウアザミ属(Ageratum spp.)を含む有効量の組成物を投与することを含み、前記症状が軽減されることを特徴とする方法。
- 請求項1に記載の方法において、前記カッコウアザミ属(Ageratum spp.)が、カッコウアザミ(Ageratum conyzoides)、アゲラタム・コエルレウム(Ageratum coeruleum)及びオオカッコウアザミ(Ageratum houstonianum)からなる群から選択されることを特徴とする方法。
- 請求項1に記載の方法において、更に前記組成物が、5−アルファ−レダクターゼ2型活性を阻害するのに有効であることを特徴とする方法。
- 請求項3に記載の方法において、前記カッコウアザミ属(Ageratum spp.)が、カッコウアザミ(Ageratum conyzoides)であることを特徴とする方法。
- 請求項1に記載の方法において、前記カッコウアザミ属(Ageratum spp.)が、カッコウアザミ(Ageratum conyzoides)であり、更に、1日総用量に対するカッコウアザミ(Ageratum conyzoides)の前記有効量が約50mg〜約500mgの範囲内であることを特徴とする方法。
- 請求項1に記載の方法において、前記カッコウアザミ属(Ageratum spp.)が、カッコウアザミ(Ageratum conyzoides)であり、更に、1日総用量に対するカッコウアザミ(Ageratum conyzoides)の前記有効量が約250mgであることを特徴とする方法。
- 請求項1に記載の方法において、前記カッコウアザミ属(Ageratum spp.)が、カッコウアザミ(Ageratum conyzoides)であり、更に、1日総用量に対するカッコウアザミ(Ageratum conyzoides)の前記有効量が約2.5mg/kg〜約3.5mg/kgであることを特徴とする方法。
- 請求項1に記載の方法において、前記症状が、尿意頻数、尿意切迫、炎症、尿路閉塞及び尿路感染症からなる群から選択されることを特徴とする方法。
- 男性ヒト対象における良性前立腺肥大症に伴う泌尿器症状を処置するための方法において、そのような処置が必要な前記対象にカッコウアザミ属(Ageratum spp.)を含む有効量の組成物を投与することを含み、前記泌尿器症状が軽減されることを特徴とする方法。
- 請求項9に記載の方法において、前記カッコウアザミ属(Ageratum spp.)が、カッコウアザミ(Ageratum conyzoides)、アゲラタム・コエルレウム(Ageratum coeruleum)及びオオカッコウアザミ(Ageratum houstonianum)からなる群から選択されることを特徴とする方法。
- 請求項9に記載の方法において、更に前記組成物が、5−アルファ−レダクターゼ2型活性を阻害するのに有効であることを特徴とする方法。
- 請求項11に記載の方法において、前記カッコウアザミ属(Ageratum spp.)が、カッコウアザミ(Ageratum conyzoides)であることを特徴とする方法。
- 請求項9に記載の方法において、前記カッコウアザミ属(Ageratum spp.)が、カッコウアザミ(Ageratum conyzoides)であり、更に、1日総用量に対するカッコウアザミ(Ageratum conyzoides)の前記有効量が約50mg〜約500mgの範囲内であることを特徴とする方法。
- 請求項9に記載の方法において、前記カッコウアザミ属(Ageratum spp.)が、カッコウアザミ(Ageratum conyzoides)であり、更に、1日総用量に対するカッコウアザミ(Ageratum conyzoides)の前記有効量が約250mgであることを特徴とする方法。
- 請求項14に記載の方法において、前記泌尿器症状が毎日の尿意頻数であることを特徴とする方法。
- 請求項15に記載の方法において、1日排尿頻度が1日あたり約2回減少することを特徴とする方法。
- 請求項16に記載の方法において、前記組成物が約12週間にわたり投与されることを特徴とする方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862692299P | 2018-06-29 | 2018-06-29 | |
US62/692,299 | 2018-06-29 | ||
PCT/US2019/039890 WO2020006455A1 (en) | 2018-06-29 | 2019-06-28 | Herbal extract composition and method for improving and managing benign prostatic hypertrophy (bph) and related aging symptoms using extract from ageratum spp. |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021530454A true JP2021530454A (ja) | 2021-11-11 |
JPWO2020006455A5 JPWO2020006455A5 (ja) | 2022-05-11 |
Family
ID=68985859
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020572400A Pending JP2021530454A (ja) | 2018-06-29 | 2019-06-28 | カッコウアザミ属(Ageratum spp.)からの抽出物を使用して良性前立腺肥大症(BPH)及び関連する加齢症状を改善及び管理するための薬用植物抽出組成物及び方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US11071763B2 (ja) |
EP (1) | EP3813943A4 (ja) |
JP (1) | JP2021530454A (ja) |
KR (1) | KR20210032400A (ja) |
CN (1) | CN112955218A (ja) |
AU (1) | AU2019295776B2 (ja) |
WO (1) | WO2020006455A1 (ja) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04342535A (ja) * | 1991-07-12 | 1992-11-30 | Rohto Pharmaceut Co Ltd | テストステロン5α−リダクターゼ阻害剤 |
JPH11335232A (ja) * | 1998-05-21 | 1999-12-07 | Maruzen Seiyaku Kk | テストステロン5α−レダクターゼ阻害剤 |
JP2000044439A (ja) * | 1998-07-31 | 2000-02-15 | Shiseido Co Ltd | 頭皮頭髪用組成物 |
JP2004161623A (ja) * | 2002-11-11 | 2004-06-10 | Noevir Co Ltd | 水性スティック状抗アクネ用組成物 |
WO2005087245A1 (ja) * | 2004-03-15 | 2005-09-22 | Nippon Shinyaku Co., Ltd. | テストステロン5α−リダクターゼ阻害剤 |
JP2006182701A (ja) * | 2004-12-27 | 2006-07-13 | Tokyo Rika Kikai Kk | テストステロン−5α−レダクターゼ阻害剤 |
JP2006273755A (ja) * | 2005-03-29 | 2006-10-12 | Nippon Menaade Keshohin Kk | テストステロン−5α−レダクターゼ阻害剤 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1336232A (zh) * | 2001-09-03 | 2002-02-20 | 李永忠 | 一种纯生物增寿制品 |
WO2006039807A1 (en) | 2004-10-15 | 2006-04-20 | Biopharmacopae Design International Inc. | Methods and therapeutic compositions comprising plant extracts for the treatment of cancer |
EP1664322B1 (en) | 2003-05-22 | 2013-07-10 | Fraunhofer USA, Inc. | Recombinant carrier molecule for expression, delivery and purification of target polypeptides |
US20050084547A1 (en) * | 2003-09-12 | 2005-04-21 | Phytomyco Research Corporation | Natural product based apoptosis inducers |
CN101623455B (zh) * | 2009-08-13 | 2011-01-19 | 陈静静 | 一种治疗前列腺增生的药物 |
CN106265947A (zh) * | 2016-11-08 | 2017-01-04 | 何杰斌 | 湿热慢性前列腺炎中药配方 |
WO2018163192A1 (en) * | 2017-03-06 | 2018-09-13 | Jagannathan V T | Herbal extract for promoting and managing benign prostatic hypertrophy (bph) and related ageing symptoms using extract from ageratum spp. |
-
2019
- 2019-06-28 KR KR1020217002676A patent/KR20210032400A/ko unknown
- 2019-06-28 AU AU2019295776A patent/AU2019295776B2/en active Active
- 2019-06-28 EP EP19825827.9A patent/EP3813943A4/en not_active Withdrawn
- 2019-06-28 US US16/456,698 patent/US11071763B2/en active Active
- 2019-06-28 WO PCT/US2019/039890 patent/WO2020006455A1/en unknown
- 2019-06-28 JP JP2020572400A patent/JP2021530454A/ja active Pending
- 2019-06-28 CN CN201980047174.4A patent/CN112955218A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04342535A (ja) * | 1991-07-12 | 1992-11-30 | Rohto Pharmaceut Co Ltd | テストステロン5α−リダクターゼ阻害剤 |
JPH11335232A (ja) * | 1998-05-21 | 1999-12-07 | Maruzen Seiyaku Kk | テストステロン5α−レダクターゼ阻害剤 |
JP2000044439A (ja) * | 1998-07-31 | 2000-02-15 | Shiseido Co Ltd | 頭皮頭髪用組成物 |
JP2004161623A (ja) * | 2002-11-11 | 2004-06-10 | Noevir Co Ltd | 水性スティック状抗アクネ用組成物 |
WO2005087245A1 (ja) * | 2004-03-15 | 2005-09-22 | Nippon Shinyaku Co., Ltd. | テストステロン5α−リダクターゼ阻害剤 |
JP2006182701A (ja) * | 2004-12-27 | 2006-07-13 | Tokyo Rika Kikai Kk | テストステロン−5α−レダクターゼ阻害剤 |
JP2006273755A (ja) * | 2005-03-29 | 2006-10-12 | Nippon Menaade Keshohin Kk | テストステロン−5α−レダクターゼ阻害剤 |
Non-Patent Citations (1)
Title |
---|
BIOFACTORS, vol. 43(6), JPN6023008010, 2017, pages 789 - 800, ISSN: 0005000925 * |
Also Published As
Publication number | Publication date |
---|---|
CN112955218A (zh) | 2021-06-11 |
WO2020006455A1 (en) | 2020-01-02 |
US20200000865A1 (en) | 2020-01-02 |
AU2019295776B2 (en) | 2023-05-18 |
EP3813943A4 (en) | 2022-06-15 |
US11071763B2 (en) | 2021-07-27 |
KR20210032400A (ko) | 2021-03-24 |
EP3813943A1 (en) | 2021-05-05 |
AU2019295776A1 (en) | 2021-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | Dendrobium officinale polysaccharide attenuates type 2 diabetes mellitus via the regulation of PI3K/Akt-mediated glycogen synthesis and glucose metabolism | |
US7465466B2 (en) | Compositions and methods for prostate and kidney health and disorders, an herbal preparation | |
Wang et al. | Phytoecdysteroids from Ajuga iva act as potential antidiabetic agent against alloxan-induced diabetic male albino rats | |
Rahman et al. | Cryptotanshinone, a compound of Salvia miltiorrhiza inhibits pre-adipocytes differentiation by regulation of adipogenesis-related genes expression via STAT3 signaling | |
KR20150038302A (ko) | 치료제로서의 크로몬 | |
Manouchehri et al. | Polycystic ovaries and herbal remedies: A systematic review | |
Hossain et al. | Hot methanol extract of Leea macrophylla (Roxb.) manages chemical-induced inflammation in rodent model | |
Nurudeen et al. | Aqueous root extract of Lecaniodiscus cupanioides restores the alterations in testicular parameters of sexually impaired male rats | |
TW200427455A (en) | Water soluble extract from plant of solanum genus and the preparation process thereof, and pharmaceutical composition containing the water soluble extract | |
Wang et al. | A phytosterol enriched refined extract of Brassica campestris L. pollen significantly improves benign prostatic hyperplasia (BPH) in a rat model as compared to the classical TCM pollen preparation Qianlie Kang Pule’an Tablets | |
Li et al. | Dietary supplementation of chinese ginseng prevents obesity and metabolic syndrome in high-fat diet-fed mice | |
Seo et al. | Peanut sprout rich in p-coumaric acid ameliorates obesity and lipopolysaccharide-induced inflammation and the inhibition of browning in adipocytes via mitochondrial activation | |
Li et al. | Eriobotrya japonica leaf triterpenoid acids ameliorate metabolic syndrome in C57BL/6J mice fed with high-fat diet | |
Chouhan et al. | Anti-inflammatory activity of ethanol extract of Vitex glabrata leaves | |
Azgomi et al. | Potential roles of genistein in polycystic ovary syndrome: A comprehensive systematic review | |
Ogunlakin et al. | Ameliorative effect of kigelia africana (Lam.) benth. fruit methanol extract in letrozole-induced polycystic ovarian syndrome rat | |
KR20180101411A (ko) | 전립선 비대증 치료를 위한 약제학적 조성물 | |
US7449202B1 (en) | Compositions and methods for prostate and kidney health and disorders, an herbal preparation | |
JP2021530454A (ja) | カッコウアザミ属(Ageratum spp.)からの抽出物を使用して良性前立腺肥大症(BPH)及び関連する加齢症状を改善及び管理するための薬用植物抽出組成物及び方法 | |
WO2018163192A1 (en) | Herbal extract for promoting and managing benign prostatic hypertrophy (bph) and related ageing symptoms using extract from ageratum spp. | |
Xu et al. | Dangshen Huangjiu prevents gastric mucosal injury and inhibits Akt/NF-κB pathway | |
JP2021508735A (ja) | ゴカヒ、ロコン、及びアカマツ抽出物を有効成分として含む前立腺疾患の予防、治療、又は改善用組成物 | |
Hong et al. | Effect of black cohosh on genital atrophy and its adverse effect in postmenopausal women | |
KR102168459B1 (ko) | 전립선 문제를 해결하기 위한 치료제로서 쿠르쿠마 망가 발 에 지프 추출물 | |
Selvaraj et al. | Transcriptional regulation of the pregnane-X receptor by the Ayurvedic formulation Chandraprabha Vati |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220427 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220427 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230228 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230228 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230531 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230731 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230831 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230831 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231114 |